Federal Contractor Profile
Albert B. Sabin Vaccine Institute, INC. (the)
Federal contracting record: $574M obligated across 3 awards from 1 agencies, FY 2019–2026.
$574M
Total Obligated
3
Award Records
1
Agencies Served
1
NAICS Codes
Company Profile
Parent UEI (Unique Entity Identifier)
H5E8NU6N2HZ5
CAGE Code
5MPW2
Address
2175 K STREET NW SUITE 400, WASHINGTON, DC, 200371848
First Federal Award
Sep 26, 2019
Most Recent Award
Aug 19, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$574M
100.0% of total obligations
Top NAICS Activity
- $574M
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Aug 19, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP) | $40M → |
| May 11, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $4.3M → |
| May 5, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP) | $224M → |
| Jul 29, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $39M → |
| Jul 8, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $1.6M → |
| May 1, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $13M → |
| Dec 16, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $17M → |
| Sep 25, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $17M → |
| Jul 23, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $2.5M → |
| May 21, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $777K → |
| Aug 23, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $28M → |
| Aug 2, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $36M → |
| Feb 14, 2023 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $799K → |
| Dec 29, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE SCOPE OF THE PROPOSED PROGRAM INCLUDES MANUFACTURE OF SABIN?S SUDAN EBOLAVIRUS VACCINE (BULK DRUG SUBSTANCE (BDS) AND FINAL DRUG PRODUCT (FDP)) TO PROVIDE DOSES THAT MAY BE USED IN THE EVENT OF AN OUTBREAK SCENARIO. THE PROPOSED EFFORT WILL UTILI | $35M → |
| Dec 19, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $861K → |
| Oct 21, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $16M → |
| Aug 17, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $22M → |
| May 27, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $463K → |
| Jan 18, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $1.2M → |
| Sep 1, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $35M → |
| May 5, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $20M → |
| Sep 26, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | $21M → |
Want to win work like Albert B. Sabin Vaccine Institute, INC. (the)?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.